Exero Medical

Focus: Exero Medical is an Israeli medical device biotech (founded 2018) focused on post-operative tissue healing monitoring, specifically in colorectal surgery applications. The company operates at pre-revenue stage with a single platform technology targeting surgical leak detection.

Oncology

Profile data last refreshed 2d ago · AI intelligence enriched 2w ago

Open Jobs

About Exero Medical

AI assessmentNot Hiring

No open roles listed right now. Follow Exero Medical to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

3 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

xBar™ System

Colorectal Cancer

N/A

Clinical Trials (1)

NCT07337590Anastomotic Safety and Surveillance Using Real-time Enhanced Sensing Using xBar

N/A

Help build intelligence for Exero Medical

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage opportunity to shape a novel medical device category in post-operative monitoring with high unmet clinical need in colorectal surgery
Focused pipeline with 3 trials underway on the xBar system, offering clear visibility into near-term validation milestones
International biotech location (Israel) provides exposure to emerging innovation hubs and potential exit/acquisition pathways

Watch Out For

No active job openings currently listed, signaling either hiring pause, full staffing, or limited near-term expansion
Pre-revenue stage with no disclosed funding, cash position, or financial runway—restructuring risk is material if clinical or commercial validation stalls
Extremely early-stage pipeline (no traditional Phase 1/2/3 classification) limits visibility on clinical safety/efficacy and regulatory pathway clarity

Generated by Claude from Exero Medical's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

xBar system

Colorectal Surgery

N/A

Clinical Trials (1)

NCT06168669A Safety and Effectiveness Prospective Blinded Clinical Study to Validate xBar System as Monitoring Tool for Anastomotic Leaks Detection

N/A

Exero Medical Leak Detection System

Open/ Laparoscopic/ Robotic Resection of the Colon

N/A

Clinical Trials (1)

NCT04854473Collection of Electrophysiological Data During Colon Resection

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Founded: 2018

Portfolio: 3 clinical trials

Top TAs: Oncology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Oncology

1 pipeline

Marketed

Pipeline